Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su TAR-200 in combinazione con Cetrelimab o TAR-200 da solo rispetto al bacillo intravescicale di Calmette-Guérin (BCG) in partecipanti con carcinoma della vescica non muscolo-invasivo ad alto rischio naïve al BCG (SunRISe-3)

24 settembre 2026 aggiornato da: Janssen Research & Development, LLC

Uno studio di fase 3, in aperto, multicentrico, randomizzato che valuta l'efficacia e la sicurezza di TAR-200 in combinazione con Cetrelimab o TAR-200 da solo rispetto al bacillo intravescicale Calmette-Guérin (BCG) in partecipanti ad alto rischio naïve al BCG Cancro della vescica non muscolo-invasivo

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1135

Fase

  • Fase 3

Accesso esteso

Approvato per la vendita al pubblico. Vedi record di accesso esteso.

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Buenos Aires, Argentina, C1199
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1417
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • Córdoba, Argentina, X5016KEH
        • Hospital Privado Centro Medico de Cordoba
      • Córdoba, Argentina, 5000
        • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
      • Córdoba, Argentina, X5000KPH
        • Centro Urologico Profesor Bengio
      • Mar del Plata, Argentina, B7602CBM
        • Hospital Privado de la Comunidad
      • Río Cuarto, Argentina, 5800
        • Instituto Medico Rio Cuarto
      • Heidelberg, Australia, 3084
        • Austin Health
      • Macquarie University, Australia, 2109
        • Macquarie University Hospital
      • Nedlands, Australia, 6009
        • Hollywood Private Hospital
      • South Brisbane, Australia, 4101
        • Mater Hospital Brisbane
      • Antwerp, Belgio, 2020
        • ZNA Middelheim
      • Bruges, Belgio, 8000
        • AZ Sint-Jan
      • Bruges, Belgio, 8310
        • AZ Sint-Lucas
      • Ghent, Belgio, 9000
        • AZ Maria Middelares
      • Ghent, Belgio, 9000
        • UZ Gent
      • Libramont-Chevigny, Belgio, 6800
        • Centre Hospitalier de l'Ardenne
      • Roeselare, Belgio, 8800
        • AZ Delta
      • Sint-Niklaas, Belgio, 9100
        • Vitaz
      • Wilrijk, Belgio, 2610
        • GZA Ziekenhuizen- Campus St Augustinus
      • Barretos, Brasile, 14784-400
        • Fundacao Pio XII
      • Bauru, Brasile, 17033-495
        • NAIC Nair Antunes Instituto do Cancer
      • Campinas, Brasile, 13083-888
        • Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
      • Curitiba, Brasile, 81520-060
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Natal, Brasile, 59075-740
        • Liga Norte Riograndense Contra O Cancer
      • Porto Alegre, Brasile, 90050-170
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Presidente Prudente, Brasile, 19013-050
        • Hospital Regional do Cancer Hospital de Esperanca
      • Salvador, Brasile, 41253-190
        • IDOR - Regional Bahia
      • Santa Cruz do Sul, Brasile, 96835-090
        • Hospital Ana Nery Santa Cruz do Sul
      • Santo André, Brasile, 09060-870
        • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
      • São Paulo, Brasile, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasile, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • São Paulo, Brasile, 05652 900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasile, 1321 001
        • Real e Benemerita Associacao Portuguesa de Beneficencia
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Nova Scotia Health Authority
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
        • St Josephs Healthcare Hamilton
      • Toronto, Ontario, Canada, M5G 1Z5
        • Princess Margaret Cancer Centre University Health Network
    • Quebec
      • Montreal, Quebec, Canada, H2X 3E4
        • CHUM - Centre hospitalier universitaire de Montreal
      • Québec, Quebec, Canada, G1J1Z4
        • CHU de Quebec Universite Laval Hopital de l Enfant Jesus
      • Saint Jerome Quebec, Quebec, Canada, J7Z 2V4
        • Unite de Recherche Clinique du CISSS des Laurentides
      • Brno, Cechia, 65691
        • Fakultni nemocnice u sv. Anny v Brne
      • Hradec Králové, Cechia, 500 05
        • Fakultni nemocnice Hradec Kralove
      • Liberec, Cechia, 460 01
        • Krajská nemocnice Liberec a.s.
      • Olomouc, Cechia, 779 00
        • Fakultni nemocnice Olomouc
      • Prague, Cechia, 100 34
        • Fakultni nemocnice Kralovske Vinohrady
      • Prague, Cechia, 15006
        • Fakultni nemocnice v Motole
      • Prague, Cechia, 140 59
        • Thomayerova nemocnice, Onkologicka klinika
      • Beijing, Cina, 100730
        • Beijing Hospital
      • Beijing, Cina, 100034
        • Peking University First Hospital
      • Beijing, Cina, 101100
        • Beijing Luhe Hospital, Capital Medical University
      • Changchun, Cina, 130499
        • The First Bethune Hospital of Jilin University
      • Changsha, Cina, 410013
        • Hunan Province Cancer Hospital
      • Chengdu, Cina, 610044
        • West China Hospital Sichuan University
      • Chongqing, Cina, 400000
        • Chongqing University Cancer Hospital
      • Deyang, Cina, 618000
        • People's Hospital of Deyang City
      • Guangzhou, Cina, 430030
        • Sun Yat Sen University Cancer Center
      • Hangzhou, Cina, 310000
        • Zhejiang Provincial People's Hospital
      • Hangzhou, Cina, 310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Nanjing, Cina, 210008
        • Nanjing Drum Tower Hospital
      • Ningbo, Cina, 315010
        • The First Affiliated Hospital of Ningbo University
      • Shanghai, Cina, 200025
        • Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
      • Shanghai, Cina, 200400
        • Huadong Hospital Affiliated to Fudan University
      • Shenyang, Cina, 110004
        • Shengjing Hospital Of China Medical University
      • Tianjin, Cina, 300211
        • The Second Hospital Of Tianjin Medical University
      • Wenzhou, Cina, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Cina, 430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Xi'an, Cina, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Yantai, Cina, 264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou, Cina, 450008
        • Henan Cancer Hospital
      • Busan, Corea del Sud, 49241
        • Pusan National University Hospital
      • Cheongju-si, Corea del Sud, 28644
        • Chungbuk National University Hospital
      • Daegu, Corea del Sud, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Corea del Sud, 42601
        • Keimyung University Dongsan Hospital
      • Gyeonggi-do, Corea del Sud, 10408
        • National Cancer Center
      • Jeollanam-do, Corea del Sud, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, Corea del Sud, 03080
        • Seoul National University Hospital
      • Seoul, Corea del Sud, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Corea del Sud, 06351
        • Samsung Medical Center
      • Seoul, Corea del Sud, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Corea del Sud, 06591
        • The Catholic University of Korea Seoul St Marys Hospital
      • Seoul, Corea del Sud, 02841
        • Korea University Anam Hospital
      • Bordeaux, Francia, 33000
        • Polyclinique Bordeaux Nord Acquitaine
      • Clermont-Ferrand, Francia, 63003
        • CHU Gabriel-Montpied
      • Grenoble, Francia, 38043
        • CHU Grenoble
      • Limoges, Francia, 87000
        • Polyclinique de Limoges - Francois Chenieux
      • Lyon, Francia, 69437
        • Hôpital Edouard Herriot
      • Nantes, Francia, 44093
        • CHU de Nantes hotel Dieu
      • Nîmes, Francia, 30029
        • CHU Nimes
      • Orléans, Francia, 45067
        • Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
      • Paris, Francia, 75013
        • Hôpital Universitaire Pitié-Salpêtrière
      • Paris, Francia, 75018
        • APHP - Hopital Bichat - Claude Bernard
      • Paris, Francia, 75960
        • Groupe Hospitalier Diaconesses Croix Saint Simon
      • Paris, Francia, 75015
        • Hopital Europeen Georges-Pompidou
      • Quint-Fonsegrives, Francia, 31130
        • Clinical La Croix Du Sud - Ramsay Santé
      • Rennes, Francia, 35000
        • Chu Rennes Hopital Pontchaillou
      • Strasbourg, Francia, 67200
        • Institut de Cancerologie Strasbourg Europe ICANS
      • Toulouse, Francia, 31059
        • CHU Rangueil
      • Cologne, Germania, 50968
        • Urologische Partnerschaft Koln UPK
      • Duisburg, Germania, 47169
        • Urologicum Duisburg
      • Erlangen, Germania, 91054
        • Universitatsklinikum Erlangen
      • Essen, Germania, 45147
        • Universitatsklinikum Essen
      • Frankfurt am Main, Germania, 60590
        • Universitaetsklinikum Frankfurt
      • Freiburg im Breisgau, Germania, 79106
        • Universitaetsklinikum Freiburg
      • Markkleeberg, Germania, 04416
        • Matthias Schulze - Germany
      • Mettmann, Germania, 40822
        • Urologie Neandertal Praxis Mettmann
      • München, Germania, 81675
        • Klinikum rechts der Isar an der Technischen Universitat Munchen
      • Münster, Germania, 48149
        • Universitatsklinikum Munster
      • Nuremberg, Germania, 90491
        • Medizinisches Versorgungszentrum - Urologie
      • Nuremberg, Germania, 90419
        • Klinikum Nurnberg Nord
      • Nürtingen, Germania, 72622
        • Studienpraxis Urologie Nurtingen
      • Regensburg, Germania, 93053
        • Caritas-Krankenhaus St. Josef
      • Tübingen, Germania, 72076
        • Universitat Tubingen
      • Fuji-shi, Giappone, 417-8567
        • Fuji City General Hospital
      • Kanazawa, Giappone, 920 8641
        • Kanazawa University Hospital
      • Kashihara-shi, Giappone, 634-8522
        • Nara Medical University Hospital
      • Kisarazu-shi, Giappone, 292-8535
        • Kimitsu Chuo Hospital
      • Kobe, Giappone, 650 0047
        • Kobe City Medical Center General Hospital
      • Kumamoto, Giappone, 860-0008
        • National Hospital Organization Kumamoto Medical Center
      • Nagano, Giappone, 381-8551
        • Nagano Municipal Hospital
      • Nagasaki, Giappone, 852-8501
        • Nagasaki University Hospital
      • Nagasaki, Giappone, 852-8511
        • JRC Nagasaki Genbaku Hospital
      • Narashino-shi, Giappone, 275-8580
        • Saiseikai Narashino Hospital
      • Toon-shi, Giappone, 791-0295
        • Ehime University Hospital
      • Toyama, Giappone, 930 0194
        • Toyama University Hospital
      • Ube, Giappone, 755-8505
        • Yamaguchi University Hospital
      • Yokohama, Giappone, 232 0024
        • Yokohama City University Medical Center
      • Bangalore, India, 560027
        • Health Care Global Enterprises pvt Ltd
      • Chandigarh, India, 160012
        • Post Graduate Institute of Medical Education And Research PGIMER
      • Gurugram, India, 122001
        • Artemis Hospital
      • Kolkata, India, 700094
        • Netaji Subhas chandra Bose Cancer Research Institute
      • Mumbai, India, 400012
        • Tata Memorial Hospital
      • Pune, India, 411040
        • CIMET s Inamdar Multispeciality Hospital
      • Acquaviva delle Fonti, Italia, 70021
        • Generale Regionale F. Miulli
      • Asti, Italia, 14100
        • Ospedale Cardinal Massaia
      • Avellino, Italia, 83100
        • Ospedale San Giuseppe Moscati di Avellino
      • Castelfranco Veneto, Italia, 31033
        • Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
      • Milan, Italia, 20141
        • Istituto Europeo di Oncologia
      • Milan, Italia, 20132
        • Ospedale San Raffaele di Milano
      • Naples, Italia, 80138
        • Fondazione G Pascale Istituto Nazionale Tumori IRCCS
      • Ravenna, Italia, 48121
        • Ospedale S. Maria Delle Croci
      • Rome, Italia, 00128
        • Istituto Nazionale Tumori Regina Elena
      • Mexico City, Messico, 14308
        • Consultorio Medico dentro del Hospital Angeles Acoxpa
      • Monterrey, Messico, 64460
        • Hospital Universitario Dr Jose Eleuterio Gonzalez
      • Monterrey, Messico, 64710
        • Avix Investigacion Clinica S C
      • Mérida, Messico, 97000
        • Eme Red Hospitalaria
      • San Luis Potosí City, Messico, 78260
        • Oncologico Potosino
      • Hoofddorp, Olanda, 2134 TM
        • Spaarne Gasthuis
      • Nijmegen, Olanda, 6524 KD
        • Canisius-Wilhelmina Ziekenhuis
      • Nijmegen, Olanda, 6525 GA
        • Radboud Umcn
      • Bialystok, Polonia, 15 276
        • Uniwersytecki Szpital Kliniczny w Bialymstoku
      • Bydgoszcz, Polonia, 85 048
        • IN VIVO Sp. z o.o
      • Lublin, Polonia, 20 708
        • Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
      • Piotrkow Trybunalski, Polonia, 97 300
        • Centrum Medyczne
      • Poznan, Polonia, 61 731
        • Clinical Research Center sp z o o MEDIC R s k
      • Słupsk, Polonia, 76-200
        • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
      • Warsaw, Polonia, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Warsaw, Polonia, 02-647
        • Provita Poliklinika
      • Wroclaw, Polonia, 50 556
        • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
      • Coimbra, Portogallo, 3000-075
        • Ipo Coimbra
      • Lisbon, Portogallo, 1769 001
        • Uls Santa Maria - Hosp. Santa Maria
      • Vila Nova de Gaia, Portogallo, 4434 502
        • Uls Gaia Espinho
      • Edinburgh, Regno Unito, EH4 2XU
        • Western General Hospital
      • London, Regno Unito, W6 8RF
        • Charing Cross Hospital
      • London, Regno Unito, SW3 6JJ
        • The Royal Marsden NHS Trust
      • London, Regno Unito, EC1A 7BE
        • St Bartholomews Hospital
      • Plymouth, Regno Unito, PL6 8DH
        • Derriford Hospital
      • Scunthorpe, Regno Unito, DN15 7BH
        • Scunthorpe General Hospital
      • Sheffield, Regno Unito, S10 2JF
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Stevenage, Regno Unito, SG1 4AB
        • Lister Hospital
      • Truro, Regno Unito, TR1 3LJ
        • Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
      • A Coruña, Spagna, 15006
        • Hosp Univ A Coruna
      • Algeciras, Spagna, 11207
        • Hosp. Punta de Europa
      • Barcelona, Spagna, 08025
        • Fund. Puigvert
      • Cadiz, Spagna, 11009
        • Hosp. Puerta Del Mar
      • Castellon, Spagna, 12004
        • Hosp. Gral. Univ. de Castellon
      • L'Hospitalet de Llobregat, Spagna, 08907
        • Hosp. Univ. de Bellvitge
      • Lugo, Spagna, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, Spagna, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spagna, 28046
        • Hosp. Univ. La Paz
      • Madrid, Spagna, 28027
        • Clinica Univ. de Navarra
      • Málaga, Spagna, 29010
        • Hosp Virgen de La Victoria
      • Santander, Spagna, 39008
        • Hosp. Univ. Marques de Valdecilla
      • Valencia, Spagna, 46010
        • Hosp. Clinico Univ. de Valencia
    • Arizona
      • Scottsdale, Arizona, Stati Uniti, 85259
        • Mayo Clinic
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72211
        • Arkansas Urology
    • California
      • Long Beach, California, Stati Uniti, 90822
        • VA Long Beach Health Care System
      • Los Alamitos, California, Stati Uniti, 90720
        • Genesis Research, LLC - West Coast Urology
      • Los Angeles, California, Stati Uniti, 90048
        • Cedars Sinai Medical Center
      • Sacramento, California, Stati Uniti, 95630
        • UC Davis Comprehensive Cancer Center
      • San Diego, California, Stati Uniti, 92123
        • Genesis Research
      • Santa Monica, California, Stati Uniti, 90404
        • Providence Saint Johns Cancer Institute
      • Santa Rosa, California, Stati Uniti, 95403
        • Providence Medical Foundation
    • Colorado
      • Lakewood, Colorado, Stati Uniti, 80228
        • Colorado Clinical Research
    • Florida
      • Hialeah, Florida, Stati Uniti, 33016
        • Urological Research Network
      • Orlando, Florida, Stati Uniti, 32806
        • Orlando Health Cancer Institute
      • Sarasota, Florida, Stati Uniti, 34239
        • Sarasota Memorial Hospital
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30303
        • Grady Memorial Hospital
      • Atlanta, Georgia, Stati Uniti, 30322
        • The Emory Clinic Department of Urology
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Northwestern University
      • Lisle, Illinois, Stati Uniti, 60532
        • Duly Health and Care
      • Quincy, Illinois, Stati Uniti, 62301
        • Blessing Hospital
    • Indiana
      • Carmel, Indiana, Stati Uniti, 46032
        • Urology of Indiana
      • Jeffersonville, Indiana, Stati Uniti, 47130
        • First Urology
    • Kansas
      • Merriam, Kansas, Stati Uniti, 66204
        • AMR Kansas City Oncology
      • Wichita, Kansas, Stati Uniti, 67226
        • Wichita Urology Group
    • Maryland
      • Hanover, Maryland, Stati Uniti, 21076
        • Chesapeake Urology Research Associates
    • Massachusetts
      • Burlington, Massachusetts, Stati Uniti, 01805
        • Lahey Hospital & Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • University Of Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68114
        • The Urology Center, PC
    • New Jersey
      • Camden, New Jersey, Stati Uniti, 08103
        • Cooper Health System MD Anderson Cancer Center at Cooper
    • New York
      • New York, New York, Stati Uniti, 10029
        • Icahn School of Medicine at Mt. Sinai
      • New York, New York, Stati Uniti, 10010
        • VA NY Harbor Healthcare System
      • Syracuse, New York, Stati Uniti, 13210
        • SUNY Upstate Med Univ
      • Syracuse, New York, Stati Uniti, 13210
        • Associated Medical Professionals of Ny
    • North Carolina
      • Greenville, North Carolina, Stati Uniti, 27834
        • Vidant Urology - Greenville
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44195
        • Cleveland Clinic
      • Gahanna, Ohio, Stati Uniti, 43230
        • Central Ohio Urology Group
    • Pennsylvania
      • Bala-Cynwyd, Pennsylvania, Stati Uniti, 19004
        • Centers for Advanced Urology LLC d b a MidLantic Urology
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • UPMC Shadyside Hospital
    • South Carolina
      • Myrtle Beach, South Carolina, Stati Uniti, 29572
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Stati Uniti, 37209
        • Urology Associates
    • Texas
      • Austin, Texas, Stati Uniti, 78745
        • Urology Austin
      • Dallas, Texas, Stati Uniti, 75231
        • Urology Clinics of North Texas
      • Houston, Texas, Stati Uniti, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Stati Uniti, 77027
        • Houston Metro Urology
      • San Antonio, Texas, Stati Uniti, 78229
        • Urology San Antonio Research
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute
      • Salt Lake City, Utah, Stati Uniti, 84148
        • George E. Wahlen VAMC
    • Virginia
      • Virginia Beach, Virginia, Stati Uniti, 23462
        • Urology Of Virginia, Pllc
    • Washington
      • Spokane, Washington, Stati Uniti, 99202
        • Spokane Urology
      • Kaohsiung City, Taiwan, 833
        • Chang Kung Memorial Hospital
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Taichung, Taiwan, 404
        • China Medical University Hospital
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taoyuan, Taiwan, 33382
        • Linkou Chang Gung Memorial Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
  • BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
  • All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
  • Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
  • All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
  • Participants must be willing to undergo all study procedures

Exclusion Criteria:

  • Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
  • Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
  • Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
  • A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
  • Indwelling catheters are not permitted; however, intermittent catheterization is acceptable

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment Group A: TAR-200 + Cetrelimab

Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.

Cetrelimab will be administered.

Altri nomi:
  • JNJ-63723283

TAR-200 will be administered intravesically.

Altri nomi:
  • JNJ-17000139
Comparatore attivo: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture

Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).

BCG will be administered intravesically.

Sperimentale: Treatment Group C: TAR-200 Alone

Participants will receive intravesical TAR-200 alone once Q3W.

TAR-200 will be administered intravesically.

Altri nomi:
  • JNJ-17000139

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Event-free Survival (EFS)
Lasso di tempo: Up to 5 years 2 months

EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first.

Up to 5 years 2 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Complete Response (CR) Rate
Lasso di tempo: Up to 5 years 2 months

Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months.

Up to 5 years 2 months
Duration of CR
Lasso di tempo: Up to 5 years 2 months

Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR.

Up to 5 years 2 months
Recurrence-Free Survival (RFS)
Lasso di tempo: Up to 5 years 2 months

RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first.

Up to 5 years 2 months
Time to Progression (TTP)
Lasso di tempo: Up to 5 years 2 months

TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first.

Up to 5 years 2 months
Overall Survival (OS)
Lasso di tempo: Up to 5 years 2 months

OS is defined as the time from randomization to death, due to any cause.

Up to 5 years 2 months
Cancer Specific Survival (CSS)
Lasso di tempo: Up to 5 years 2 months

CSS is defined as the time from randomization to the date of death due to bladder cancer.

Up to 5 years 2 months
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE)
Lasso di tempo: Up to 5 years 2 months

Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event.

Up to 5 years 2 months
Number of Participants with Adverse Events (AEs)
Lasso di tempo: Up to 5 years 2 months

Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Up to 5 years 2 months
Number of Participants with Change from Baseline in Laboratory Abnormalities
Lasso di tempo: Up to 5 years 2 months

Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event.

Up to 5 years 2 months
Number of Participants with Change from Baseline in Vital Signs Abnormalities
Lasso di tempo: Up to 5 years 2 months

Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported.

Up to 5 years 2 months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24
Lasso di tempo: Up to 5 years 2 months

EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Up to 5 years 2 months
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores
Lasso di tempo: Up to 5 years 2 months

EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Up to 5 years 2 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 marzo 2023

Completamento primario (Stimato)

18 settembre 2029

Completamento dello studio (Stimato)

18 settembre 2029

Date di iscrizione allo studio

Primo inviato

27 gennaio 2023

Primo inviato che soddisfa i criteri di controllo qualità

27 gennaio 2023

Primo Inserito (Effettivo)

6 febbraio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CR109223
  • 2020-004506-64 (Numero EudraCT)
  • 17000139BLC3002 (Altro identificatore: Janssen Research & Development, LLC)
  • 2023-507187-39-00 (Identificatore di registro: EUCT number)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .